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Staphylococcus aureus is the leading cause of bloodstream, lower respiratory tract, skin, and soft tissue infections in the United States (Klevens et al., 2007) . Methicillin-resistant S. aureus (MRSA) strains are isolated in more than half of all community and hospital infections (Klevens et al., 2008) . MRSA strains harbor methicillin resistance genes, rendering the entire class of -lactam antimicrobials obsolete as therapeutic agents (Berger-Bächi, 1994) . Some MRSA isolates also acquired resistance to vancomycin, the antibiotic of last resort. These strains threaten a return to the preantibiotic era (Chang et al., 2003) . Thus, there is an urgent need for vaccines that protect against staphylococcal infection.
S. aureus infection in humans is not associated with the generation of protective immunity, as patients often suffer recurrent bouts of skin and soft tissue infections (Lowy, 1998) . Recent advances described several mechanisms for staphylococcal escape from innate host defenses (de Haas et al., 2004; Rooijakkers et al., 2005; Thammavongsa et al., 2009) ; however, the molecular events underlying the escape from adaptive immune responses during staphylococcal infection are not known. Human diseases caused by S. aureus can be recapitulated in animals.
In particular, experimental infections of the lung, skin, or soft tissues and internal organs have been established in mice (Bubeck Wardenburg et al., 2008; Cheng et al., 2009) . Using these models and molecular genetics approaches, staphylococcal protein A (SpA), a cell wall-anchored surface protein (Sjöquist et al., 1972) , was identified as a crucial virulence factor for lung infections, septicemia, and abscess development (Palmqvist et al., 2002; Gómez et al., 2004; Cheng et al., 2009) .
The vast majority of clinical S. aureus isolates express SpA (Forsgren, 1970; Shopsin et al., 1999) , which binds to the Fc portion of most Ig subclasses (Jensen, 1958; Lindmark et al., 1983) , V H 3 type B cell receptors (Sasso et al., 1989) , von Willebrand factor (vWF; Hartleib et al., 2000) , and TNFR1 (Gómez et al., 2004) . Interaction of SpA with B cell receptors (IgM) leads to clonal expansion and subsequent cell death of B cell populations with effects on adaptive and innate immune responses (Forsgren and Quie, 1974; Forsgren et al., 1976; Goodyear and Silverman, 2004;  RESULTS AND DISCUSSION SpA is a virulence factor for lethal S. aureus infections The contribution of the spa gene toward lethal S. aureus challenge has thus far not been appreciated. To address this, we generated the isogenic spa deletion variant S. aureus Newman spa. After intraperitoneal challenge with 2 × 10 8 CFU of wild-type S. aureus Newman, 60% of animals succumbed to challenge. In contrast, animals infected with the isogenic mutant resulted in only 25% mortality (Fig. S1 A) . In addition, the spa mutant displayed a consistent survival defect when examined in naive mouse blood (see Fig. 3 D) . These results suggest that SpA is a crucial virulence factor for lethal infections of S. aureus in mice.
SpA-D KKAA cannot bind to immunoglobulin and trigger B cell apoptosis Guided by amino acid homology, the triple -helical bundle structure of Ig binding domains (Deisenhofer, 1981) , and their atomic interactions with Fab V H 3 (Graille et al., 2000) or Fc (Gouda et al., 1998) , we selected glutamine 9 and 10, as well as aspartate 36 and 37, as critical for the association of SpA with immunoglobulin ( Fig. 1, A and B; and Fig. S2, A and B) . To test this, substitutions Gln 9 Lys, Gln 10 Lys, Asp 36 Ala, and Asp 37 Ala were introduced into the D domain to generate SpA-D KKAA (Fig. 1 B) . The ability of isolated SpA-D or SpA-D KKAA to bind human IgG or IgM was analyzed by affinity chromatography and ELISA (Fig. 1, C and D) . Polyhistidine-tagged SpA-D, as well as full-length SpA, retained human IgG on Ni-NTA, whereas SpA-D KKAA or a negative control (sortase A; Mazmanian et al., 1999) did not (Fig. 1, C and D) . A similar result was observed with vWF (Hartleib et al., 2000) , which, along with TNFR1 (Gómez et al., 2004) , can also bind SpA via glutamines 9 and 10 (Gómez et al., 2006;  Fig. 1 D) . Human Ig encompasses 50% V H 3-type IgG (Cook and Tomlinson, 1995) . Human Fc and F(ab) 2 fragments, as well as IgM, all Silverman and Goodyear, 2006) . In contrast, SpA binding to the Fc of Ig interferes with opsonophagocytic clearance of staphylococci by polymorphonuclear leukocytes (Peterson et al., 1977) . SpA is synthesized as a precursor with an N-terminal signal peptide and a C-terminal sorting signal for covalent anchoring to the cell wall (Schneewind et al., 1992) . The N-terminal part of mature SpA is comprised of four or five 56-61-residue Ig binding domains (Sjödahl, 1977) , which fold into triple helical bundles connected by short linkers (Deisenhofer, 1981) . The C-terminal region X is comprised of Xr, a highly repetitive yet variable octapeptide, and Xc, a domain of unique sequence which abuts the cell wall anchor structure of SpA (Guss et al., 1984; Schneewind et al., 1995) .
As a result of the attribute of simultaneously binding Fc and Fab, SpA vaccines with neutralizing antibodies and protective immunity have hitherto not been reported (Greenberg et al., 1989) . We wondered whether antibodies that neutralize the immunosuppressive properties of SpA could affect the outcome of S. aureus infections. 
full-length SpA were higher than those elicited by SpA-D (P = 0.0022), which is likely a result of the larger size and reiterative domain structure of this antigen (Table I) . Nevertheless, even SpA elicited lower antibody titers than SpA-D KKAA (P = 0.0003), which encompasses only 50 aa of the mature 520-residue protein. Immunized mice were challenged by intravenous inoculation with S. aureus Newman, and the ability of staphylococci to seed abscesses in renal tissues was examined by necropsy 4 d after challenge (Cheng et al., 2009) . In homogenized renal tissue of mock (PBS/adjuvant) immunized mice, a mean staphylococcal load of 6.46 log 10 CFU g 1 was enumerated (Table I) . Immunization of mice with SpA or SpA-D led to a reduction in staphylococcal load; however, SpA-D KKAA -vaccinated animals displayed an even greater 3.07 log 10 CFU g 1 reduction of S. aureus Newman in renal tissues (P < 0.0001; Table I ). Abscess formation in kidneys was analyzed by histopathology ( Fig. S3 A-H) . Mock immunized animals harbored a mean of 3.7 (±1.2) abscesses per kidney (Table I) . Vaccination with SpA-D KKAA reduced the mean number of abscesses to 0.5 (±0.4; P = 0.0204), whereas immunization with SpA or SpA-D did not cause a significant reduction in the number of abscess lesions (Table I) . Lesions from SpA-D KKAA -vaccinated animals were smaller in size, with fewer infiltrating PMNs, and characteristically lacked staphylococcal abscess communities (Cheng et al., 2009; Fig. S3, A-H) . Abscesses in animals that had been immunized with SpA or SpA-D displayed the same overall structure of lesions in mock immunized animals ( Fig. S3 , A-H).
We wondered whether SpA-D KKAA immunization could protect mice against MRSA strains and selected the USA300 bound to full-length SpA or SpA-D but not to SpA-D KKAA (Fig. 1 D) . Injection of SpA-D into the peritoneal cavity of mice resulted in B cell expansion followed by apoptotic collapse of CD19 + (or CD45R + ) lymphocytes in the spleen tissue of BALB/c or C57BL/6 mice (Goodyear and Silverman, 2003 ; Fig. 1 E) . B cell superantigen activity was not observed after injection with SpA-D KKAA , and TUNEL-staining of splenic tissue failed to detect the increase in apoptotic cells that follows injection of SpA or SpA-D ( Table I ). Antibody titers raised by immunization with (Diep et al., 2006) . This highly virulent CA-MRSA strain spread rapidly throughout the United States, causing significant human morbidity and mortality. Compared with adjuvant control mice, SpA-D KKAAimmunized animals harbored a 1.20 log 10 CFU g 1 reduction in bacterial load of infected kidney tissues. Histopathology examination of renal tissue after S. aureus USA300 challenge revealed that the mean number of abscesses was reduced from 4.0 (±0.8) to 1.6 (±0.6; P = 0.0277). In contrast, SpA or SpA-D immunization did not cause a significant reduction in bacterial load or abscess formation (Table I; matrices with immobilized cognate antigen and injected at a concentration of 5 mg × kg 1 body weight into the peritoneal cavity of BALB/c mice (Table II) . 24 h later, antibody titers specific for SpA-D KKAA /SpA KKAA were determined in serum and animals challenged by intravenous inoculation with S. aureus Newman. Passive transfer reduced the staphylococcal load in kidney tissues for SpA-D KKAA -(P = 0.0016) or SpA KKAA (P = 0.0005)-specific antibodies. On histopathology examination, both antibodies reduced the abundance of abscess lesions in kidneys of mice challenged with S. aureus Newman (Table II) . Compared with control cohorts treated with nonspecific antibody (-V10), animals that had been injected with SpA-specific antibodies were protected against the B cell superantigen activity of SpA (Fig. S2, C and D) . In addition, SpA-specific antibodies (2 µg × ml 1 ) induced opsonophagocytic clearance of S. aureus Newman inoculated into naive mouse blood (Fig. 3 D) and reduced the mortality associated with lethal staphylococcal challenge (Fig. S1 C) . Together these data reveal that disease protection after immunization with SpA-D KKAA or SpA KKAA is conferred by antibodies that bind SpA and neutralize its ability to bind Ig.
SpA KKAA immunization promotes host antibody response to staphylococcal infection
After infection with virulent S. aureus Newman and clearance of the pathogen with antibiotic treatment, mice do not develop protective immunity against subsequent infection with the same strain (Fig. S3 S) . The mean abundance of SpA-D KKAA -specific IgG in these animals was determined by dot blot as 0.20 µg ml 1 (±0.04) and 0.14 µg ml 1 (±0.01) for infections caused by S. aureus strains Newman and USA300 LAC, respectively (Fig. 4 A) . A concentration of 4.05 µg ml 1 (±0.88) for SpA-specific IgG was estimated to confer disease protection in SpA KKAA -or SpA-D KKAA -immunized mice (P ≤ 0.05 log 10 reduction in staphylococcal CFU g 1 renal tissue; unpublished data). The mean serum concentration of SpAspecific IgG in adult healthy human volunteers (n = 16) was 0.21 µg ml 1 (±0.02). Such antibody concentration may not be sufficient to generate protection against staphylococcal A, B, and C; Sjödahl, 1977) . Polyhistidine-tagged SpA KKAA was purified by affinity chromatography and analyzed by Coomassie blue-stained SDS-PAGE (Fig. 3 A) . Unlike full-length SpA, SpA KKAA did not bind human IgG, Fc and F(ab) 2 , IgM, or vWF (Fig. 3 B) . SpA KKAA failed to display B cell superantigen activity, as injection of the variant into BALB/c or C57BL/6 mice did not cause a depletion of both CD19 + and CD45R + B cells in splenic tissue (Fig. 3 C; Fig. S2 , C and D; and not depicted). SpA KKAA immunization generated higher specific antibody titers than SpA-D KKAA and provided mice with elevated protection against S. aureus USA300 (Table I) or Mu50 challenge (Fig. S3 U; Mu50 is a Japanese MRSA isolate). 4 d after challenge, SpA KKAA -vaccinated animals harbored 3.54 log 10 CFU g 1 fewer staphylococci in renal tissues (P = 0.0001) and also caused a greater reduction in the number of abscess lesions (P = 0.0109; Table I ; and Fig. S3 , I-R). Furthermore, SpA KKAA immunization reduced the mortality of mice that received a lethal S. aureus challenge dose (Fig. S1 B) . Staphylococci persist in mouse organ tissues (Cheng et al., 2009) . Over time, abscesses harboring communities of the infectious agent increase in size and eventually rupture, thereby releasing staphylococci into circulation. This initiates the formation of new abscesses and precipitates lethal outcomes 30-60 d after challenge (Cheng et al., 2009) . We asked whether SpA-D KKAA or SpA KKAA immunization prevents staphylococcal replication over a longer period of time. 15 d after challenge with S. aureus USA300, immunization with SpA did not generate significant protection of animals compared with the mock control (P = 0.5817; Table S1 ). In contrast, immunization with SpA-D KKAA caused a 1.56 log 10 CFU g 1 reduction (P = 0.0183), whereas SpA KKAA vaccination reduced the load by 2.7 log 10 CFU g 1 (P = 0.0059). These data suggest that antibodies against SpA, generated via active immunization using nontoxigenic SpA KKAA , can interfere with bacterial persistence in host tissues.
SpA-specific antibodies generate protective immunity
SpA KKAA was used to immunize rabbits. Rabbit antibodies specific for SpA-D KKAA or SpA KKAA were affinity purified on (unpublished data). Mock immunized mice (adjuvant only) that had been subjected to USA300 infection developed hightiter antibodies against the Eap protein as well as low-titer antibodies against Hla, IsdA, IsdB, LukD, LukE, and LukF (Fig. 4 B) . In response to USA300 challenge, animals that had been immunized with SpA KKAA (IgG titer 2,907 [±357]; P < 0.001, SpA KKAA vs. mock) mounted humoral immune responses against every antigen examined (Fig. 4 B) . With the exception of Eap, IsdA, and IsdB antibodies, the serum of SpA KKAA -immunized animals harbored higher antibody titers against staphylococcal antigens as compared with mice that had been naive at the time of challenge (Fig. 4 B) . In summary, S. aureus isolates express SpA, an essential virulence factor whose B cell superantigen activity and evasive attributes toward opsonophagocytic clearance are required for staphylococcal abscess formation and the establishment of lethal disease (Cheng et al., 2009) . SpA can be thought of as a toxin that is essential for pathogenesis and whose molecular attributes must be neutralized to achieve protective immunity. By generating nontoxigenic variants unable to bind Igs via Fc or V H 3-Fab domains, we identified SpA-neutralizing immune responses as a correlate for protective immunity against S. aureus infection. In contrast to many methicillin-sensitive strains, the CA-MRSA isolate USA300 LAC is significantly more virulent (Cheng et al., 2009 ). For example, immunization of experimental animals infection. By comparison, the mean serum concentration of IgG specific for diphtheria toxin in human volunteers, 0.68 µg ml 1 (± 0.20), is thought to be within range for protective immunity against diphtheria (Lagergård et al., 1992) . These results are in agreement with a model of immune evasion during S. aureus infection. Cell wall-anchored or secreted SpA (e.g., 20% of peptidoglycan and attached surface protein is released during bacterial division; Ton-That et al., 1999) activate B cells via IgM receptor cross-linking. Without stimuli from specific antigens, activated B cells undergo apoptosis, thereby hindering the production of antibody against staphylococcal antigens. If so, neutralizing antibodies directed against SpA may enable humoral immune responses against many different staphylococcal antigens. This was tested by immunizing BALB/c mice with SpA KKAA or an adjuvant (aluminum hydroxide) control, followed by intravenous challenge with a sublethal dose of MRSA strain USA300. Serum samples were withdrawn 30 d after MRSA challenge and then analyzed by immunoblotting with 27 staphylococcal antigens immobilized on a membrane filter (Fig. 4 B) . Naive mice, which had not been infected with the MRSA strain USA300 LAC, did not harbor antibodies against staphylococcal antigens 
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peroxidase-conjugated human IgG, Fc, or F(ab) 2 fragments, IgM (The Jackson Laboratory), and vWF (Thermo Fisher Scientific) and developed using OptEIA reagent. For inhibition, plates were incubated with either naive rabbit F(ab) 2 fragments (The Jackson Laboratory) or 10 µg ml 1 of affinitypurified F(ab) 2 fragments before ligand binding.
B cell apoptosis. 150 µg of purified protein was injected into the peritoneum of 6-wk-old BALB/c. 4 h after injection, animals were killed and spleens removed and homogenized. Red blood cells were lysed in ACK buffer. White blood cells were stained with R-PE-conjugated anti-CD19 (eBioscience). Cells were washed and fixed with formalin and analyzed by FACSCanto (BD).
Antibody quantification. Nitrocellulose membrane was blotted with human/ mouse IgG (The Jackson Laboratory), SpA KKAA , and CRM 197 , blocked, and incubated with either human or mouse sera. IRDye 700DX-conjugated antihuman/mouse IgG (Rockland Immunochemicals, Inc.) was used to quantify signal intensities from healthy human volunteers or mice using the Odyssey infrared imaging system (LI-COR Biosciences). Experiments with blood from human volunteers involved protocols that were reviewed, approved, and performed under regulatory supervision of The University of Chicago's Institutional Review Board. For the staphylococcal antigen matrix, nitrocellulose membrane was blotted with 2 µg of a collection of Ni-NTA affinity-purified recombinant His 6 -tagged staphylococcal proteins. Signal intensities in mouse sera were quantified and normalized using anti-His 6 antibody with the Odyssey.
Statistical Analysis. Unpaired two-tailed Student's t tests were performed to analyze the statistical significance of renal abscess, ELISA, and B cell superantigen data.
Online supplemental material. Fig. S1 shows that SpA is a virulence factor for lethal infection after intraperitoneal injection of S. aureus Newman into BALB/c mice and that active or passive immunization with antibodies raised against SpA KKAA can protect against this disease. Fig. S2 shows that SpA KKAA , unlike wild-type SpA, does not induce B cell apoptosis in mice and that antibodies raised against SpA KKAA neutralize the B cell superantigen attributes of SpA. Fig. S3 shows that immunization of mice with SpA KKAA prevents multiple S. aureus strains from inducing renal abscess formation in mice and that prior infection with S. aureus does not elicit immunity to subsequent infection with the same strain. Online supplemental material is available at http://www .jem.org/cgi/content/full/jem.20092514/DC1. with the surface protein IsdB (Kuklin et al., 2006) raises antibodies that confer protection against S. aureus Newman (Kuklin et al., 2006) but not against USA300 challenge (Fig. S3 T) . In contrast, neutralizing SpA antibody responses generate protection against strains of the current MRSA epidemic. These antibodies exert at least two functions. As shown in Fig. 3 , the SpA antibodies enable phagocytic killing of staphylococci in blood. Moreover, by neutralizing B cell superantigen activity, SpA antibodies enable the development of humoral immune responses to many different antigens that, assuming synergism, may together contribute toward the establishment of immunity. In agreement with this, the SpA KKAA vaccine elicited greater protection against abscess formation, which monitors infected animals over a prolonged period of time (Fig. 4) , as compared with the lethal challenge, when most animals die within 1-2 d (Fig. S1 ).
MATERIALS AND METHODS
Antibody isolation. 5 mg of protein was covalently linked to HiTrap NHS-activated HP and loaded with rabbit serum. Antibodies were eluted with 1 M glycine, pH 2.5, and 0.5 M NaCl, neutralized with 1 M Tris-HCl, pH 8.5, and dialyzed against PBS. Affinity-purified antibodies were mixed with 3 mg pepsin at 37°C for 30 min and quenched with 1 M Tris-HCl, pH 8.5. F(ab) 2 fragments were again affinity purified, dialyzed against PBS at 4°C, separated by 15% SDS-PAGE, and visualized with Coomassie Blue.
Active and passive immunization. The coding sequence for SpA was PCR amplified with two primers, 5-GCTGCACATATGGCGCAACACGAT-GAAGCTCAAC-3 and 5-AGTGGATCCTTATGCTTGAGCTTTGTT-AGCATCTGC-3, using S. aureus Newman DNA. SpA-D was PCR amplified with two primers: 5-AACATATGTTCAACAAAGATCAACAAAGC-3 and 5-AAGGATCCAGATTCGTTTAATTTTTTAGC-3. The sequence for SpA-D KKAA was mutagenized with two sets of primers: 5-CATATGTTCA-ACAAAGATAAAAAAAGCGCCTTCTATGAAATC-3 and 5-GATTTC-ATAGAAGGCGCTTTTTTTATCTTTGTTGAACATATG-3 for Q9K and Q10K, and 5-CTTCATTCAAAGTCTTAAAGCCGCCCCAAGC-CAAAGCACTAAC-3 and 5-GTTAGTGCTTTGGCTTGGGGCGGCT-TTAAGACTTTGAATGAAG-3 for D36A and D37A. The sequence of SpA KKAA was synthesized by Integrated DNA Technologies, Inc. PCR products were cloned into pET-15b generating N-terminal His 6 -tagged recombinant protein. BALB/c mice were immunized by intramuscular injection and boosted with the same antigen after 11 d. On day 20, mice were bled to obtain serum for specific antibody titers. Affinity-purified antibodies were injected into the peritoneal cavity of BALB/c mice at 4-24 h, and blood was collected for specific antibody titers before challenge.
Mouse infection. Staphylococci were used to infect anesthetized mice by retroorbital injection (1 × 10 7 CFU S. aureus Newman, 5 × 10 6 CFU S. aureus USA300, or 3 × 10 7 CFU S. aureus Mu50). On day 4, 15, or 30, mice were killed, kidneys removed, and homogenized tissue spread on agar for colony formation. Animal experiments were performed in agreement with the institutional guidelines according to experimental protocol review and approval by the Institutional Biosafety Committee and the Institutional Animal Care and Use Committee at the University of Chicago.
Bacterial survival in blood. As previously described (Thammavongsa et al., 2009) , whole blood was collected from BALB/c mice with 5 µg ml 1 of lepirudin anticoagulant. 50 µl of 5 × 10 4-6 CFU ml 1 S. aureus Newman were mixed with 950 µl of mouse blood. Samples were incubated at 37°C with slow rotation for 30 min and then incubated on ice with 1% saponin/PBS. Dilutions of staphylococci were plated on agar for colony formation.
SpA ligands. 1 µg ml 1 of purified SpA and its variants were coated onto ELISA plates in 0.1 M carbonate buffer, pH 9.5. Plates were incubated with
